Current situation and the latest progress in the treatment of pyoderma gangrenosum / 中华烧伤杂志
Chinese Journal of Burns
; (6): 574-579, 2022.
Article
em Zh
| WPRIM
| ID: wpr-940963
Biblioteca responsável:
WPRO
ABSTRACT
Pyoderma gangrenosum (PG) is a rare chronic inflammatory non-infectious skin dermatosis, and there is no clear treatment guideline for this disease at home and abroad. There are a variety of clinical treatment methods for PG, including local therapy and systemic application of glucocorticoids, immunosuppressants, intravenous immuno- globulin, and biologics. Glucocorticoids are the first-line drugs commonly used in clinical practice, and immunosuppressants can be used alone or in combination with glucocorticoids. In recent years, more and more evidence has shown that biologics are a new trend in the treatment of PG, mainly including tumor necrosis factor α inhibitors, interleukin-1 (IL-1) inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, rituximab, and small molecular inhibitors. This article summarizes the current status and latest progress in the treatment of PG, hoping to provide clinicians with ideas for the treatment of PG.
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Produtos Biológicos
/
Pioderma Gangrenoso
/
Inibidores de Interleucina
/
Glucocorticoides
/
Imunossupressores
/
Imunoterapia
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
Zh
Revista:
Chinese Journal of Burns
Ano de publicação:
2022
Tipo de documento:
Article